Related Experiment Video
Updated: May 21, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Transcription Factor DLX5 As a New Target for Promising Antitumor Agents
R A Timakhov1, P O Fedichev, A A Vinnik
1Quantum Pharmaceuticals, Russia.
Acta Naturae
|June 1, 2012
Summary
Researchers screened compounds using the DLX5 protein structure, identifying Q12 as a promising cancer treatment. This compound inhibits DLX5-positive lymphoma cell growth with low toxicity, offering potential for new cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- The human transcription factor DLX5 plays a role in cellular processes.
- Targeting transcription factors is a strategy in cancer therapy.
Purpose of the Study:
- To identify novel inhibitors of DLX5 activity for cancer treatment.
- To screen a large compound library against the DLX5 crystal structure.
Main Methods:
- Molecular docking was employed to screen a library of 10^6 compounds against the DLX5 crystal structure.
- In vitro assays were performed on top-ranked compounds.
- Cell proliferation and gene expression (c-MYC) were analyzed.
Main Results:
- Compound Q12 demonstrated the highest efficacy in inhibiting DLX5-positive mouse lymphoma cell proliferation.
- Q12 treatment correlated with decreased c-MYC expression.
- Low toxicity was observed in normal human ovarian epithelial cells and DLX5-negative lymphoma cells.
Conclusions:
- Compound Q12 is a potent inhibitor of DLX5-positive lymphoma cell proliferation.
- Q12 exhibits favorable toxicity profiles, suggesting its potential for further development.
- This study provides a basis for developing novel, efficient cancer treatments targeting DLX5.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...